Kiromic BioPharma, Inc. Common Stock
KRBP
KRBP was delisted on the 13th of September, 2023.
23 hedge funds and large institutions have $7.49M invested in Kiromic BioPharma, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 3 closing their positions.
665% more call options, than puts
Call options by funds: $1.51M | Put options by funds: $197K
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
53% more funds holding
Funds holding: 15 → 23 (+8)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
17.71% less ownership
Funds ownership: 33.51% → 15.8% (-18%)
37% less capital invested
Capital invested by funds: $11.9M → $7.49M (-$4.42M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$607K |
| 2 |
1CM
1492 Capital Management
Milwaukee,
Wisconsin
|
+$263K |
| 3 |
LPL Financial
San Diego,
California
|
+$182K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$178K |
| 5 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
+$138K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$1.6M |
| 2 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$481K |
| 3 |
FIA
FNY Investment Advisers
New York
|
-$288K |
| 4 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$176K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$77.3K |
KRBP Hedge Fund Activity: Q3 2021 in Review
23 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Kiromic BioPharma, Inc. Common Stock (KRBP) for Q3 2021, worth a combined $7.49M — down 37% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new KRBP positions and 3 closed out — a net gain of 8 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $607K. The largest seller was Altium Capital Management, exiting entirely with an estimated $1.6M sold.
- 23 institutional investors held Kiromic BioPharma, Inc. Common Stock (KRBP) as of Q3 2021, up from 15 in Q2 2021.
- Funds reported $7.49M of Kiromic BioPharma, Inc. Common Stock stock for Q3 2021, down 37% quarter-over-quarter.
- 11 funds opened new Kiromic BioPharma, Inc. Common Stock positions in Q3 2021 and 3 closed out, a net change of +8 holders.
- The largest Kiromic BioPharma, Inc. Common Stock buyer in Q3 2021 was Vanguard Group, an estimated $607K added.
- The largest Kiromic BioPharma, Inc. Common Stock seller in Q3 2021 was Altium Capital Management, an estimated $1.6M sold.
Based on aggregated 13F filings for Q3 2021.